Tumor cells with defective antiviral pathways

Tumor cells with defective antiviral pathways represent a cellular phenotype where innate immune defenses, particularly the Type I Interferon (IFN) signaling cascade, are impaired (Kaufman et al., 2015, Nature Reviews Drug Discovery). In healthy cells, the detection of viral components triggers the production of IFNs, which activate downstream genes to halt protein synthesis and induce apoptosis, preventing viral spread (Xia et al., 2016, Cell Reports). Many cancers selectively disable these pathways—through mutations or epigenetic silencing of components like STING, IRF3, or STAT1—to evade immune surveillance and facilitate unchecked growth (Bommareddy et al., 2018, Nature Reviews Immunology). This specific deficiency creates a therapeutic window for oncolytic virotherapy, as these viruses can selectively replicate within and destroy compromised tumor cells while being cleared by the intact defenses of normal tissue. Upon infecting these cells, the viruses cause direct oncolysis, releasing a cocktail of tumor-associated antigens and inflammatory cytokines into the microenvironment. This process effectively converts immunologically cold tumors into hot ones, recruiting and activating T-cells to mount a systemic anti-tumor response. Consequently, the defective antiviral state serves both as a mechanism for viral selectivity and a catalyst for broader immunotherapy.

Other names

Interferon-deficient tumor cellsAntiviral-deficient cancer cellsOncolytic virus-susceptible tumor cellsIFN-non-responsive tumor cells

Exploitation of impaired innate antiviral defenses (specifically the Type I Interferon pathway) to allow selective viral replication, direct cell lysis, and induction of systemic anti-tumor immunity (Kaufman et al., 2015).